Metabolomics

PreclinicalBiologic

DDirection Centrale du Service de Santé des Armées

Metabolomics is one of 3 biologic programs targeting Virtual Reality. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Virtual RealityUnknown status

Virtual RealityPreclinical

Unknown status

Competition

Competitive Landscape

2 competitors in Virtual Reality

#DrugCompanyPhaseTrials

Administration of Almitrine

CCentre Hospitalier Universitaire de Nice

Phase 3

1 2

Selective Alpha 1-Blockers

SSamsung Medical Center

Preclinical

1 3

Metabolomics

DDirection Centrale du Service de Santé des Armées

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Virtual Reality1 trial

Clinical Impact and Neuro-functional Substrate of Immersive Virtual Reality Sports Practice on Depression

Unknown status·DDirection Centrale du Service de Santé des Armées·N/A·NCT05019183·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Metabolomics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metabolomics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metabolomics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Direction Centrale du Service de Santé des Armées company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: DDirection Centrale du Service de Santé des Armées

Metabolomics

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Virtual Reality1 trial

References

Drug Info

Quick Facts

Related News